Vanguard Group Inc. Buys 54,528 Shares of Orthofix Medical Inc. $OFIX

Key Points

• Vanguard Group Inc. increased its stake in Orthofix Medical by 2.6% in the first quarter, now owning approximately 5.59% of the company, worth $35.58 million.
• The recent earnings report showed Orthofix Medical had a loss of ($0.36) earnings per share, significantly missing analyst estimates of $0.04.
• Analysts have mixed views on the stock, with one upgrading it to a "strong-buy" rating and setting a price target of $16.00, while the consensus price target remains at $21.50.

Vanguard Group Inc. boosted its stake in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 2.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,181,313 shares of the medical device company's stock after purchasing an additional 54,528 shares during the quarter. Vanguard Group Inc. owned approximately 5.59% of Orthofix Medical worth $35,577,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in OFIX. Lazard Asset Management LLC bought a new position in Orthofix Medical in the 4th quarter worth about $45,000. US Bancorp DE boosted its stake in Orthofix Medical by 684.6% in the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock worth $93,000 after purchasing an additional 4,950 shares during the period. Tower Research Capital LLC TRC boosted its stake in Orthofix Medical by 120.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock worth $148,000 after purchasing an additional 4,627 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Orthofix Medical in the 1st quarter worth about $164,000. Finally, State of Wyoming boosted its stake in Orthofix Medical by 206.8% in the 4th quarter. State of Wyoming now owns 9,432 shares of the medical device company's stock worth $165,000 after purchasing an additional 6,358 shares during the period. Institutional investors own 89.76% of the company's stock.

Orthofix Medical Stock Performance

Shares of NASDAQ OFIX opened at $14.51 on Wednesday. The stock has a market cap of $573.00 million, a price-to-earnings ratio of -4.58 and a beta of 0.82. The company has a current ratio of 2.67, a quick ratio of 1.50 and a debt-to-equity ratio of 0.38. Orthofix Medical Inc. has a 1-year low of $10.24 and a 1-year high of $20.73. The stock's 50-day moving average is $11.89 and its 200 day moving average is $13.54.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). The firm had revenue of $203.12 million for the quarter, compared to analysts' expectations of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.

Insider Buying and Selling at Orthofix Medical

In related news, insider Aviva Mcpherron sold 3,728 shares of the firm's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the transaction, the insider directly owned 46,322 shares of the company's stock, valued at approximately $486,844.22. This trade represents a 7.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wall Street Zen raised Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Finally, Barrington Research raised Orthofix Medical to a "strong-buy" rating and set a $16.00 price target on the stock in a report on Monday, June 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $21.50.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.